Advertisement
Screener

Sagimet Biosciences Inc. (SGMT) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

2.8 / 5 stars · 68/120 Roast Me

Sagimet Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

Sagimet Biosciences Inc. (SGMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 91.00% for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-21.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2023-08-21

  • 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month 91.00%.
  • 2022-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month 90.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month
2023-06-3091.00%
10-Q · filed 2023-08-21
2022-06-3090.00%
10-Q · filed 2023-08-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35